Abstract
Recent phase I and phase II trials using recombinant human interleukin-12 (rhIL-12) for cutaneous T cell lymphoma (CTCL) have been completed. Observations on 32 evaluable patients revealed an overall response rate approaching 50 percent. Biopsy of regressing lesions revealed an increase in numbers of CD8+ and/or TIA-1+ T cells. These results suggest that rhIL-12 may induce lesion regression by augmenting antitumor cytotoxic T cell responses. Future trials will be focused on strategies for further immune enhancement by the concomitant use of additional immune augmenting cytokines with rhIL-12.
Original language | English (US) |
---|---|
Pages (from-to) | 177-184 |
Number of pages | 8 |
Journal | Annals of the New York Academy of Sciences |
Volume | 941 |
DOIs | |
State | Published - 2001 |
Funding
Keywords
- Interferon-γ
- Interleukin-2
- Recombinant human interleukin-12
ASJC Scopus subject areas
- General Biochemistry, Genetics and Molecular Biology
- General Neuroscience
- History and Philosophy of Science